Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues
Diagnostics · 18.10.2023 · 13 (20) · 3242
DOI: 10.3390/diagnostics13203242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 18.10.2023. Verfasst von Laura Sophie Tribian und 30 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate-specific acid phosphatase (PSAP) is a marker for prostate cancer. To assess the specificity and prognostic impact of PSAP, 14,137 samples from 127 different tumor (sub)types, 17,747 prostate cancers, and 76 different normal tissue types were analyzed via immunohistochemistry in a tissue microarray format. In normal tissues, PSAP staining was limited to the prostate epithelial cells. In prostate cancers, PSAP was seen in 100% of Gleason 3 + 3, 95.5% of Gleason 4 + 4, 93.8% of recurrent cancer under androgen deprivation therapy, 91.0% of Gleason 5 + 5, and 31.2% of small cell neuroendocrine cancer. In non-prostatic tumors, PSAP immunostaining was only found in 3.2% of pancreatic neuroendocrine tumors and in 0.8% of diffuse-type gastric adenocarcinomas. In prostate cancer, reduced PSAP staining was strongly linked to an advanced pT stage, a high classical and quantitative Gleason score, lymph node metastasis, high pre-operative PSA levels, early PSA recurrence (p < 0.0001 each), high androgen receptor expression, and TMPRSS2:ERG fusions. A low level of PSAP expression was linked to PSA recurrence independent of pre- and postoperative prognostic markers in ERG-negative cancers. Positive PSAP immunostaining is highly specific for prostate cancer. Reduced PSAP expression is associated with aggressive prostate cancers. These findings make PSAP a candidate marker for prognostic multiparameter panels in ERG-negative prostate cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
- Department of General, Visceral, and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
- Institute of Pathology, Clinical Center Osnabrueck, 49076 Osnabrueck, Germany.
- Department of Pathology, Academic Hospital Fuerth, 90766 Fuerth, Germany.
ORCID-Profile: Maximilian Lennartz, Claudia Hube-Magg, Ronald Simon, Till S Clauditz
Zitieren
APA
Tribian, L. S., Lennartz, M., Höflmayer, D., de Wispelaere, N., Dwertmann Rico, S., von Bargen, C., Kind, S., Reiswich, V., Viehweger, F., Lutz, F., Bertram, V., Fraune, C., Gorbokon, N., Weidemann, S., Hube-Magg, C., Menz, A., Uhlig, R., Krech, T., Hinsch, A., …, & Bernreuther, C. (2023). Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues. Diagnostics, 13(20), 3242. https://doi.org/10.3390/diagnostics13203242
Vancouver
Tribian LS, Lennartz M, Höflmayer D, de Wispelaere N, Dwertmann Rico S, von Bargen C, et al. Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues. Diagnostics. 2023;13(20):3242. doi:10.3390/diagnostics13203242
BibTeX
@article{Tribian2023,
author = {Tribian, Laura Sophie and Lennartz, Maximilian and Höflmayer, Doris and de Wispelaere, Noémi and Dwertmann Rico, Sebastian and von Bargen, Clara and Kind, Simon and Reiswich, Viktor and Viehweger, Florian and Lutz, Florian and Bertram, Veit and Fraune, Christoph and Gorbokon, Natalia and Weidemann, Sören and Hube-Magg, Claudia and Menz, Anne and Uhlig, Ria and Krech, Till and Hinsch, Andrea and Burandt, Eike and Sauter, Guido and Simon, Ronald and Kluth, Martina and Steurer, Stefan and Marx, Andreas H and Lebok, Patrick and Dum, David and Minner, Sarah and Jacobsen, Frank and Clauditz, Till S and Bernreuther, Christian},
title = {Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {20},
pages = {3242},
doi = {10.3390/diagnostics13203242}
}
EUVIMED